Skip to content

Proto Labs PRLB Options canceled (in dollars per share)

Options canceled (in dollars per share) at other companies

Ondas, Inc.
 logo
Ondas, Inc. ONDS
$5.42+274%
Xylem logo
XylemXYL
$127.87+13.3%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$15.04
Bicara Therapeutics logo
Bicara TherapeuticsBCAX
$0.00
NextNav logo
NextNavNN
$6.87
ALH
Alliance Laundry Holdings Inc.ALH
$0.00

Other financials

Income statement

See full
Revenue$139.3M+10.4%
Gross profit$63.6M+14.2%
Operating income$9.8M+117%
Net income$8.1M+125%
EPS (diluted)$0.33+120%

Balance sheet

See full
Cash & equivalents$124.0M+49.9%
Total debt$2.6M-16.6%
Total equity$683.1M+4.0%
Total assets$778.6M+5.6%

Cash flow

See full
Operating cash flow$17.5M-4.6%
CapEx$3.5M+181%
Free cash flow$14.0M-18.2%

Valuation

See full
Market cap$1.9B+59.7%

Profitability

See full
Gross margin44.9%+0.5pp
Operating margin5.6%+1.7pp
Net margin4.7%+1.6pp
FCF margin10.4%-3.1pp

Returns & leverage

See full
Return on equity3.8%+1.6pp
Debt / equity0.0×
Current ratio3.5×+0.4×

Where this comes from

Reported directly by Proto Labs in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice.

The official record: Proto Labs’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Proto Labs's options canceled (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Proto Labs's options canceled (in dollars per share)?
Proto Labs (PRLB) reported options canceled (in dollars per share) of $57.12 in Q1 2026.
How has Proto Labs's options canceled (in dollars per share) changed year-over-year?
Proto Labs's options canceled (in dollars per share) increased by 75.1% year-over-year, from $32.63 to $57.12.
What does options canceled (in dollars per share) mean?
The weighted average price per share of stock options that were canceled during the period. This reflects the value associated with equity awards that did not reach the exercise stage. It helps investors understand the impact of equity plan adjustments on potential dilution.